Heartflow (NASDAQ:HTFL) Stock Jumps 4.4% – Still a Buy?

Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) shot up 4.4% on Friday. The company traded as high as $46.57 and last traded at $46.5990. 741,909 shares traded hands during trading, a decline of 54% from the average session volume of 1,611,652 shares. The stock had previously closed at $44.63.

More Heartflow News

Here’s some of the latest news about HTFL:

  • Positive Sentiment: A recent report says Heartflow’s Q2 revenue beat consensus and the company raised its full-year guidance—potentially supporting the stock’s recent strength. The article excerpt provided does not include the revenue figures or revised guidance details. Article: HeartFlow (HTFL) Surges as Q2 Revenue Beats Consensus and Full-Year Guidance Is Raised
  • Negative Sentiment: Put-option trading jumped to 6,628 contracts, about 558% above the reported average volume. This indicates increased demand for downside protection or bearish bets, though options activity alone does not establish traders’ outlook. Heartflow stock information
  • Negative Sentiment: Insider Campbell Rogers has reported multiple share sales, including a recent sale of 16,918 shares. Repeated selling can weigh on sentiment, although the reported transactions were made under a pre-arranged Rule 10b5-1 plan. Article: Heartflow Insider Sells 16,918 Shares

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. JPMorgan Chase & Co. boosted their price target on Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Piper Sandler reiterated an “overweight” rating and set a $64.00 price objective (up from $45.00) on shares of Heartflow in a research report on Tuesday, October 20th. Canaccord Genuity Group lifted their target price on Heartflow from $56.00 to $69.00 and gave the stock a “buy” rating in a report on Friday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Heartflow in a research report on Wednesday, November 4th. Finally, Wells Fargo & Company upped their price target on shares of Heartflow from $39.00 to $70.00 and gave the company an “overweight” rating in a research note on Friday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $60.12.

Read Our Latest Stock Report on HTFL

Heartflow Trading Up 4.3%

The stock has a market capitalization of $4.09 billion, a P/E ratio of -50.44 and a beta of 2.50. The business has a 50-day moving average price of $51.82 and a two-hundred day moving average price of $35.55.

Heartflow (NASDAQ:HTFL – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.15. Heartflow had a negative return on equity of 20.53% and a negative net margin of 33.11%. The business had revenue of $72.86 million during the quarter. During the same period last year, the firm earned ($0.27) EPS. On average, sell-side analysts forecast that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.

Insider Buying and Selling at Heartflow

In other news, CFO Vikram Verghese sold 29,714 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $50.06, for a total value of $1,487,482.84. Following the completion of the transaction, the chief financial officer directly owned 184,789 shares in the company, valued at approximately $9,250,537.34. The trade was a 13.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Farquhar sold 38,900 shares of the company’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $49.57, for a total transaction of $1,928,273.00. Following the sale, the chief executive officer directly owned 283,014 shares of the company’s stock, valued at approximately $14,029,003.98. This trade represents a 12.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 323,936 shares of company stock valued at $16,355,191 in the last ninety days. 7.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Heartflow

Several hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC raised its holdings in shares of Heartflow by 75.1% during the 3rd quarter. GAMMA Investing LLC now owns 641 shares of the company’s stock worth $32,000 after buying an additional 275 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Heartflow by 844.7% during the 3rd quarter. IFP Advisors Inc now owns 803 shares of the company’s stock worth $40,000 after buying an additional 718 shares during the last quarter. Allworth Financial LP boosted its stake in Heartflow by 56.5% in the third quarter. Allworth Financial LP now owns 828 shares of the company’s stock valued at $41,000 after buying an additional 299 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in Heartflow in the second quarter valued at about $53,000. Finally, Essential Partners LLC bought a new position in Heartflow in the first quarter valued at about $57,000.

Heartflow Company Profile

(Get Free Report)

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.

Read More

Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.